Gyre Therapeutics, Inc. (GYRE) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP Adjusted Net Income (Loss) | -4.2M | FY2026-Q1 |
| Contiva Sales (Avatrombopag Maleate) | 800K | FY2026-Q1 |
| Etorel Sales (Nintedanib Ethanesarboxylate) | 700K | FY2026-Q1 |
| ETUARY Sales (Pirfenidone) | 21M | FY2026-Q1 |
| Pirfenidone Phase 3 Patient Enrollment | 272.00 | FY2026-Q1 |
| Pirfenidone Phase 3 Clinical Research Sites | 18.00 | FY2025-Q4 |
Back to GYRE overview · GYRE earnings · GYRE holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.